The American Cancer Society announced updated guidelines on Thursday, November 12, 2026, recommending more frequent prostate cancer screening for men in the United States. The new recommendations advise most men between the ages of 50 and 69 to undergo a prostate-specific antigen (PSA) blood test every two years. Men in high-risk groups, including Black men and those with a family history of the disease, are now advised to begin screening at age 45.
These updates replace 2010 guidelines that suggested men should make their own informed decisions regarding blood testing rather than following a standardized schedule. Dr. Robert Smith, director at the Center for Early Cancer Detection, stated that the revision is based on increased evidence that PSA testing reduces mortality and the diagnosis of advanced-stage disease. The organization cited a 2025 European study involving men aged 55 to 69, which found that prostate cancer deaths were 13 percent lower among those who received screenings.
The PSA test measures a protein produced by both healthy and cancerous prostate cells. While the National Cancer Institute notes that high PSA levels do not always indicate cancer, a level above 4.0 nanograms per milliliter is generally considered abnormal and may lead to a recommendation for a biopsy. Doctors may adjust these cutoffs based on age, using 2.5 ng/mL for younger men and 5.0 ng/mL for older men. If an initial blood test shows elevated levels, the American Cancer Society noted that further steps such as urine tests or imaging may be used before proceeding to a biopsy.
The financial impact involves both insurance coverage and potential out-of-pocket costs. According to the insurance company Aflac, PSA tests typically cost between $100 and $300 for those paying out of pocket, though most private and public insurers cover the screening. Patients will see these costs or insurance claims every two years under the new cycle. The shift in policy reflects a broader change in how medical institutions balance the benefits of early detection against the risks of unnecessary biopsies or treatments for low-risk, slow-growing cancers.
The new recommendations set a precedent for standardized screening intervals rather than the previous model of "informed decision-making." Beyond clinical testing, health organizations such as Johns Hopkins Medicine suggest men can further manage risk through dietary choices, such as increasing fruit and vegetable intake and potentially incorporating soy or green tea. Following the announcement on November 12, healthcare providers are expected to integrate these biennial schedules into routine physical exams for eligible patients immediately. Men diagnosed with cancer through this process may face decisions regarding surgery, radiation, or "active surveillance" for lower-risk cases.